(Q39598601)

13 September 2017

title

Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands (English)

1 reference

13 September 2017

0 references

1 reference

4

1 reference

13 September 2017

A W M Suijkerbuijk

1

1 reference

13 September 2017

A K Lugnér

2

1 reference

13 September 2017

W van Pelt

3

1 reference

13 September 2017

L P B Verhoef

5

1 reference

13 September 2017

H E de Melker

6

1 reference

13 September 2017

G A de Wit

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

18 June 2012

1 reference

13 September 2017

1 reference

13 September 2017

volume

30

1 reference

13 September 2017

issue

35

1 reference

13 September 2017

page(s)

5199-5205

1 reference

Declining hepatitis A seroprevalence: a global review and analysis.

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Hepatitis A virus seroprevalence by age and world region, 1990 and 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995–1996 and 2006–2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Assessing the introduction of universal varicella vaccination in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Assessing the introduction of universal rotavirus vaccination in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Disease burden of foodborne pathogens in the Netherlands, 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Clinical development of a new inactivated hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Hepatitis A vaccine versus immune globulin for postexposure prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

The effectiveness and safety of hepatitis A vaccine: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Negative attitude of highly educated parents and health care workers towards future vaccinations in the Dutch childhood vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Determinants of Dutch parents' decisions to vaccinate their child

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Effect of hepatitis A vaccination programs for migrant children on the incidence of hepatitis A in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Changing epidemiology of hepatitis A infection in Izmir, Turkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

[Prevalence of anti-hepatitis A virus antibodies in chidren in Marrakech]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

An assessment of the impact of informative dropout and nonresponse in measuring health-related quality of life using the EuroQol (EQ-5D) descriptive system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Cost-effectiveness analysis of hepatitis A vaccination strategies for adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Cost-effective analysis of hepatitis A prevention in Ireland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Regional variation in the cost effectiveness of childhood hepatitis A immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Fecal-orally transmitted diseases among travelers are decreasing due to better hygienic standards at travel destination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

Incidence of Hepatitis A in Argentina after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.014

10.1016/J.VACCINE.2012.06.014

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference